IXICO plc (PHYOF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 15.84 Million USD | -3.12% |
| 2022 | 16.35 Million USD | -14.87% |
| 2021 | 19.21 Million USD | 22.85% |
| 2020 | 15.63 Million USD | 18.59% |
| 2019 | 13.18 Million USD | -2.19% |
| 2018 | 13.48 Million GBP | 122.87% |
| 2017 | 6.04 Million GBP | -18.04% |
| 2016 | 7.38 Million GBP | 74.12% |
| 2015 | 4.23 Million GBP | -21.69% |
| 2014 | 5.41 Million GBP | 5.05% |
| 2013 | 5.15 Million GBP | -51.34% |
| 2012 | 10.58 Million GBP | -43.06% |
| 2011 | 18.59 Million GBP | -24.44% |
| 2010 | 24.61 Million GBP | 403.95% |
| 2009 | 4.88 Million GBP | -42.51% |
| 2008 | 8.49 Million GBP | 104.5% |
| 2007 | 4.15 Million GBP | -49.44% |
| 2006 | 8.21 Million GBP | -41.62% |
| 2005 | 14.07 Million GBP | 86.37% |
| 2004 | 7.55 Million GBP | 9.23% |
| 2003 | 6.91 Million GBP | -43.51% |
| 2002 | 12.23 Million GBP | -13.62% |
| 2001 | 14.16 Million GBP | 148.15% |
| 2000 | 5.7 Million GBP | 78.46% |
| 1999 | 3.19 Million GBP | -14.12% |
| 1998 | 3.72 Million GBP | -48.54% |
| 1997 | 7.23 Million GBP | -27.15% |
| 1996 | 9.93 Million GBP | 2830.68% |
| 1995 | 339 Thousand GBP | 80.32% |
| 1994 | 188 Thousand GBP | -58.5% |
| 1993 | 453 Thousand GBP | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 14.74 Million GBP | -6.91% |
| 2024 Q2 | 14.6 Million USD | 0.0% |
| 2023 Q4 | 15.84 Million USD | -3.96% |
| 2023 Q1 | 16.71 Million GBP | 2.2% |
| 2023 Q3 | 16.49 Million GBP | -3.26% |
| 2023 Q2 | 17.05 Million USD | 2.02% |
| 2023 FY | 15.84 Million USD | -3.12% |
| 2022 Q1 | 18.37 Million GBP | -3.62% |
| 2022 Q2 | 17.84 Million GBP | -2.89% |
| 2022 Q3 | 17.83 Million GBP | -0.01% |
| 2022 FY | 16.35 Million USD | -14.87% |
| 2022 Q4 | 16.35 Million USD | -8.32% |
| 2021 Q3 | 19.72 Million GBP | 7.09% |
| 2021 Q1 | 18.25 Million GBP | 16.75% |
| 2021 FY | 19.21 Million USD | 22.85% |
| 2021 Q4 | 19.06 Million GBP | -3.36% |
| 2021 Q2 | 18.41 Million GBP | 0.89% |
| 2020 Q4 | 15.63 Million GBP | 4.34% |
| 2020 Q1 | 14.01 Million GBP | 6.3% |
| 2020 Q2 | 13.12 Million GBP | -6.4% |
| 2020 FY | 15.63 Million USD | 18.59% |
| 2020 Q3 | 14.98 Million GBP | 14.23% |
| 2019 Q2 | 10.12 Million GBP | -21.56% |
| 2019 FY | 13.18 Million USD | -2.19% |
| 2019 Q3 | 13.58 Million GBP | 34.22% |
| 2019 Q1 | 12.9 Million GBP | 24.84% |
| 2019 Q4 | 13.18 Million GBP | -2.96% |
| 2018 Q2 | 4.9 Million GBP | -25.93% |
| 2018 FY | 13.48 Million GBP | 122.87% |
| 2018 Q4 | 10.33 Million GBP | -24.23% |
| 2018 Q3 | 13.64 Million GBP | 178.14% |
| 2018 Q1 | 6.62 Million GBP | 46.89% |
| 2017 FY | 6.04 Million GBP | -18.04% |
| 2017 Q4 | 4.5 Million GBP | -23.23% |
| 2017 Q3 | 5.87 Million GBP | 10.88% |
| 2017 Q2 | 5.29 Million GBP | -18.85% |
| 2017 Q1 | 6.52 Million GBP | 14.88% |
| 2016 Q3 | 7.55 Million GBP | 10.16% |
| 2016 FY | 7.38 Million GBP | 74.12% |
| 2016 Q2 | 6.85 Million GBP | -32.19% |
| 2016 Q1 | 10.11 Million GBP | 138.55% |
| 2016 Q4 | 5.68 Million GBP | -24.78% |
| 2015 Q2 | 4.61 Million GBP | -35.83% |
| 2015 FY | 4.23 Million GBP | -21.69% |
| 2015 Q3 | 6.66 Million GBP | 44.51% |
| 2015 Q1 | 7.18 Million GBP | 32.82% |
| 2015 Q4 | 4.23 Million GBP | -36.41% |
| 2014 FY | 5.41 Million GBP | 5.05% |
| 2014 Q1 | 9.65 Million GBP | 87.29% |
| 2014 Q4 | 5.41 Million GBP | 0.0% |
| 2014 Q2 | 5.82 Million GBP | -39.63% |
| 2013 FY | 5.15 Million GBP | -51.34% |
| 2013 Q2 | 7.05 Million GBP | 0.0% |
| 2013 Q4 | 5.15 Million GBP | 0.0% |
| 2012 Q4 | 10.58 Million GBP | 0.0% |
| 2012 FY | 10.58 Million GBP | -43.06% |
| 2012 Q2 | 14.18 Million GBP | 0.0% |
| 2011 FY | 18.59 Million GBP | -24.44% |
| 2011 Q2 | 21.2 Million GBP | 0.0% |
| 2011 Q4 | 18.59 Million GBP | 0.0% |
| 2010 Q2 | 27.01 Million GBP | 0.0% |
| 2010 FY | 24.61 Million GBP | 403.95% |
| 2010 Q4 | 24.61 Million GBP | 0.0% |
| 2009 Q4 | 4.88 Million GBP | 0.0% |
| 2009 Q2 | 6.99 Million GBP | 0.0% |
| 2009 FY | 4.88 Million GBP | -42.51% |
| 2008 Q4 | 8.49 Million GBP | 0.0% |
| 2008 FY | 8.49 Million GBP | 104.5% |
| 2008 Q2 | 10.63 Million GBP | 0.0% |
| 2007 FY | 4.15 Million GBP | -49.44% |
| 2007 Q2 | 5.67 Million GBP | 0.0% |
| 2006 Q4 | 8.21 Million GBP | 0.0% |
| 2006 Q2 | 10.57 Million GBP | 0.0% |
| 2006 FY | 8.21 Million GBP | -41.62% |
| 2005 Q4 | 14.07 Million GBP | 0.0% |
| 2005 FY | 14.07 Million GBP | 86.37% |
| 2005 Q2 | 10.49 Million GBP | 0.0% |
| 2004 Q2 | 10.55 Million GBP | 0.0% |
| 2004 Q4 | 7.55 Million GBP | 0.0% |
| 2004 FY | 7.55 Million GBP | 9.23% |
| 2003 Q4 | 6.91 Million GBP | 0.0% |
| 2003 FY | 6.91 Million GBP | -43.51% |
| 2003 Q2 | 8.57 Million GBP | 0.0% |
| 2002 Q2 | 13.41 Million GBP | 0.0% |
| 2002 FY | 12.23 Million GBP | -13.62% |
| 2002 Q4 | 12.23 Million GBP | 0.0% |
| 2001 FY | 14.16 Million GBP | 148.15% |
| 2000 FY | 5.7 Million GBP | 78.46% |
| 1999 FY | 3.19 Million GBP | -14.12% |
| 1998 FY | 3.72 Million GBP | -48.54% |
| 1997 FY | 7.23 Million GBP | -27.15% |
| 1996 FY | 9.93 Million GBP | 2830.68% |
| 1995 FY | 339 Thousand GBP | 80.32% |
| 1994 FY | 188 Thousand GBP | -58.5% |
| 1993 FY | 453 Thousand GBP | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -685783.247% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -709.11% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -50.122% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2769.648% |
| Rebus Holdings, Inc. | 5000.00 USD | -316778.06% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 87.832% |
| Qrons Inc. | 420.00 USD | -3772257.857% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1955.93% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 43.301% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -3196.987% |
| Skye Bioscience, Inc. | 11.94 Million USD | -32.691% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 59.215% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -119.452% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -20650.587% |
| SQZ Biotechnologies Company | 107.18 Million USD | 85.218% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1006.393% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -21794.428% |
| Mesoblast Limited | 667.9 Million USD | 97.628% |
| Marizyme, Inc. | 22.01 Million USD | 28.032% |
| Genus plc | 1.02 Billion USD | 98.46% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1066.405% |
| Pharming Group N.V. | 462.85 Million USD | 96.577% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -378.233% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -3074.883% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2426.938% |
| ContraFect Corporation | 20.67 Million USD | 23.382% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -3958.73% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -4045.698% |
| IMV Inc. | 31.33 Million USD | 49.435% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -282.147% |
| MultiCell Technologies, Inc. | 126.22 USD | -12552508.937% |
| ONE Bio Corp. | 70.08 Million USD | 77.393% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1586.079% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 87.671% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -3570.0% |
| Q BioMed Inc. | 3.51 Million USD | -350.685% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 54.962% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -5964.025% |
| Biomind Labs Inc. | 73.81 Thousand USD | -21363.178% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 96.45% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -993.556% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 47.213% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -476.911% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2204.615% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -508.633% |
| GB Sciences, Inc. | 103.44 Thousand USD | -15216.702% |
| Alpha Cognition Inc. | 2.45 Million USD | -546.118% |
| HST Global, Inc. | 1526.00 USD | -1038163.63% |
| CSL Limited | 38.02 Billion USD | 99.958% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1503.687% |
| Halberd Corporation | 10.13 Thousand USD | -156290.317% |
| Enzolytics Inc. | 361.7 Million USD | 95.62% |
| Agentix Corp. | 261.39 Thousand USD | -5961.357% |
| Resverlogix Corp. | 8.11 Million USD | -95.242% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -743.712% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.651% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 66.786% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2376.941% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -69448.76% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -77.044% |
| AVAX Technologies, Inc. | 7.37 Million USD | -114.77% |
| Zenith Capital Corp. | 7410.00 USD | -213717.854% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.532% |
| Ember Therapeutics, Inc. | 184.00 USD | -8610716.848% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -4823.433% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -5962.007% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1607.389% |
| Kadimastem Ltd | 2.3 Million USD | -587.646% |
| Helix BioMedix, Inc. | 3.02 Million USD | -423.75% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 69.936% |
| BioStem Technologies, Inc. | 14.56 Million USD | -8.816% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -27650.557% |
| LadRx Corporation | 2.3 Million USD | -586.513% |
| Cell Source, Inc. | 195.17 Thousand USD | -8017.96% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4380.526% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4380.526% |
| NovAccess Global Inc. | 62.24 Thousand USD | -25352.871% |
| Affymax, Inc. | 7.44 Million USD | -112.87% |
| Itoco Inc. | 1.4 Million USD | -1031.649% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -16463.245% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -14847.078% |
| Mobile Lads Corp. | 52.00 USD | -30468944.231% |
| CytoDyn Inc. | 11.13 Million USD | -42.276% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -10981.822% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -88512.433% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -4010.271% |
| SYBLEU INC | 330.46 Thousand USD | -4694.383% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -3769.822% |
| International Stem Cell Corporation | 5.39 Million USD | -193.95% |
| Bioxytran, Inc. | 137.63 Thousand USD | -11411.285% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -5.613% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 4.434% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -19955.573% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1732.349% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -110.774% |
| Neutra Corp. | 2851.00 USD | -555631.428% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 51.108% |
| PureTech Health plc | 693.97 Million USD | 97.717% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -96.304% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -91.305% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 84.666% |
| CSL Limited | 38.02 Billion USD | 99.958% |
| Cellectis S.A. | 333.99 Million USD | 95.256% |